Urolithin A From Gut Metabolite to Therapeutic Agent: Bioavailability, Mechanisms, and Translational Insights
Journal of Food Science · 2026-03 · 91 (3)
DOI: 10.1111/1750-3841.70988 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Food Science, online erschienen am 22.03.2026. Verfasst von Huidong Yuan und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Biosystems Engineering and Food Science, National-Local Joint Engineering Research Center of Intelligent Food Technology and Equipment, Fu…. Hauptthemen laut MEDLINE: Coumarins, Gastrointestinal Microbiome. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 87 Literaturangaben. Gefördert von: the Central Guidance for Local Funds Projects of Xinjiang, the National Key Research and Development Program of China.
Abstract (Originalsprache)
Accumulating evidences have demonstrated that urolithin A (UroA) exerted a wide range of bioactivities, including antioxidant, anti‐inflammatory, and mitochondrial function‐enhancing effects, thereby highlighting its potential as a therapeutic agent for various diseases. Preclinical studies have shown that UroA induced mitophagy both in vitro and in vivo, preventing age‐associated mitochondrial dysfunction and improving lifespan and muscle function as well as enhancing exercise capacity. However, its clinical application is limited by poor oral bioavailability and considerable interindividual variability in microbial conversion, as pharmacokinetic studies indicated low plasma exposure under standard administration. Moreover, approximately 10% of individuals are classified as urolithin nonproducers, independent of age, posing an additional challenge for clinical translation. To overcome those limitations, formulation strategies such as nanoparticles and liposomes have been developed, resulting in several‐fold increases in systemic bioavailability compared with unformulated UroA. This review would provide a comprehensive overview of recent advances in the metabolism of UroA, current approaches to improve its bioavailability, safety evaluations, and elucidated the underlying mechanisms of its bioactivities. Furthermore, recent progresses in chemical and biotechnological synthesis strategies of UroA are also summarized. These insights will provide a scientific foundation for further utilization of UroA for human health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Biosystems Engineering and Food Science, National-Local Joint Engineering Research Center of Intelligent Food Technology and Equipment, Fuli Institute of Food Science, Zhejiang Key Laboratory of Agri-food Res…
- Zhejiang University Zhongyuan Institute, Zhengzhou, China.
- Zhejiang University-Wuxi, Xishan Modern Agriculture Joint Research Center, Wuxi, China.
- Food College, Shihezi University, Shihezi, China.
- School of Agriculture, Utsunomiya University, Utsunomiya, Japan.
ORCID-Profile: Changqing Wei, Jinhu Tian
Förderung
- the Central Guidance for Local Funds Projects of Xinjiang
- the National Key Research and Development Program of China
Zitieren
APA
Yuan, H., Xie, W., Tan, W., Wei, C., Qin, W., Tamura, M., Ye, X., & Tian, J. (2026). Urolithin A From Gut Metabolite to Therapeutic Agent: Bioavailability, Mechanisms, and Translational Insights. Journal of Food Science, 91(3). https://doi.org/10.1111/1750-3841.70988
Vancouver
Yuan H, Xie W, Tan W, Wei C, Qin W, Tamura M, et al. Urolithin A From Gut Metabolite to Therapeutic Agent: Bioavailability, Mechanisms, and Translational Insights. Journal of Food Science. 2026;91(3). doi:10.1111/1750-3841.70988
BibTeX
@article{Yuan2026,
author = {Yuan, Huidong and Xie, Wenjie and Tan, Wen and Wei, Changqing and Qin, Wei and Tamura, Masatsugu and Ye, Xingqian and Tian, Jinhu},
title = {Urolithin A From Gut Metabolite to Therapeutic Agent: Bioavailability, Mechanisms, and Translational Insights},
journal = {Journal of Food Science},
year = {2026},
volume = {91},
number = {3},
doi = {10.1111/1750-3841.70988}
}
EUVIMED